Diabetic Macular Edema (DME) Symptoms and Treatments

Diabetic macular edema (DME) affects about 7% of people with diabetes worldwide and is the leading cause of vision loss among diabetic retinopathy patients1 2. Managing DME early is crucial to prevent irreversible vision impairment and maintain quality of life2 3. Advances in diagnosis and treatment, including anti-VEGF therapy, have improved outcomes for many patients4 56.

Recognizing DME Symptoms

DME may be silent in its early stages, with vision changes becoming noticeable only as fluid accumulates in the macula2 . As swelling progresses, central vision deteriorates, impacting daily activities such as reading and driving3 . Common symptoms include:

• Blurred or distorted vision, often described as wavy lines or objects appearing bent2 7
• Difficulty with near vision tasks due to macular swelling2
• Diminished color perception and dull or faded colors3 7
• Central scotomas (blind spots) impairing direct vision2 7
• Floaters, which may be present due to associated diabetic retinopathy2 3
• Objects appearing different in size when viewed with each eye separately7

Without treatment, DME can progress to severe central vision loss and even legal blindness2 3. Early detection is vital since many patients may not notice symptoms until significant damage occurs2 .

Causes of Diabetic Macular Edema

DME arises as a complication of diabetic retinopathy, a microvascular disorder caused by chronic hyperglycemia damaging retinal blood vessels2 3. The breakdown of the blood-retinal barrier leads to leakage of fluid and proteins into the macula, causing retinal thickening and edema8 29.

Risk Factors

Several factors increase the risk of developing DME:

• Duration of diabetes: Longer disease duration correlates with higher risk2
• Poor glycemic control: Elevated blood sugar levels accelerate microvascular damage3 2
• Hypertension: High blood pressure worsens retinal vessel injury2 3
• Dyslipidemia: Abnormal lipid levels contribute to vascular damage2 3
• Renal impairment: Kidney disease is associated with increased severity of DME3
• Pregnancy: Hormonal changes may exacerbate diabetic retinopathy and macular edema2

The pathophysiology involves vascular leakage, ischemia, and neovascularization. Fragile new vessels formed in proliferative diabetic retinopathy leak fluid, further worsening macular swelling2 3.

Diagnosing Diabetic Macular Edema

Diagnosis of DME requires a comprehensive eye examination by a retinal specialist. Since early DME can be asymptomatic, regular screening for diabetic patients is essential2 3.

Key diagnostic steps include:

• Visual acuity testing: Measures clarity of central vision at various distances2 3
• Pupil dilation: Allows detailed examination of the retina for edema and vascular abnormalities2
• Optical coherence tomography (OCT): The gold standard imaging modality that quantifies retinal thickness and detects fluid accumulation1 2310
• Fluorescein angiography: Visualizes retinal blood flow and leakage by tracking injected dye, identifying microaneurysms and leakage sites2 3
• Intraocular pressure measurement: Helps exclude glaucoma, which can coexist with diabetic eye disease2

OCT can detect subtle retinal swelling not visible on clinical exam and helps classify DME as center-involved or non-center-involved, guiding treatment decisions2 10.

Diabetic Macular Edema Treatment Options

Treatment aims to reduce macular swelling, stabilize or improve vision, and prevent progression of vision loss2 3. Management is tailored based on the severity of edema, visual acuity, and patient-specific factors2 11.

Intravitreal Anti-VEGF Injections

Anti-vascular endothelial growth factor (anti-VEGF) agents are the first-line therapy for most patients with center-involved DME4 211. VEGF promotes abnormal blood vessel growth and leakage; blocking it reduces edema and improves vision3 12.

Common anti-VEGF drugs include:

• Aflibercept (Eylea)
• Bevacizumab (Avastin)
• Ranibizumab (Lucentis)
• Brolucizumab-dbll (Beovu)
• Faricimab-svoa (Vabysmo), which also inhibits Angiopoietin-2 for longer-lasting effects12

Treatment involves monthly intravitreal injections initially, often for 4–6 months, followed by less frequent dosing based on response12 11. Aflibercept may be preferred for patients with vision worse than 20/5012 11.

“Faricimab will sometimes need to be administered frequently to keep the disease under control.”

— Carl Regillo, MD13

Corticosteroid Injections

Intravitreal corticosteroids reduce inflammation contributing to DME and are used in patients who respond inadequately to anti-VEGF therapy or have contraindications2 36. Steroids can be delivered as injections or sustained-release implants such as dexamethasone (Ozurdex) or fluocinolone acetonide (Iluvien) 1412.

Steroid therapy carries risks including cataract formation and increased intraocular pressure, so it is generally reserved as second-line treatment3 612. Combination therapy with anti-VEGF agents may reduce retinal thickness but does not always improve visual acuity beyond anti-VEGF alone6 11.

Laser Therapy

Focal or grid laser photocoagulation targets leaking microaneurysms to reduce edema and stabilize vision2 315. Laser treatment is often used for non-center-involved DME or as adjunctive therapy when injections are insufficient2 3.

While laser can prevent further vision loss, it does not typically restore lost visual acuity and carries risks such as retinal scarring and impaired night vision2 315.

Vitrectomy

Vitrectomy surgery may be indicated in refractory cases of DME complicated by vitreomacular traction or persistent hemorrhage2 12. The procedure removes the vitreous gel and relieves traction on the macula, potentially improving edema and vision12 .

Vitrectomy is less commonly performed but can be beneficial when other treatments fail or structural abnormalities contribute to macular swelling2 .

Preventing Diabetic Macular Edema

Complete prevention of DME is not guaranteed, but risk can be significantly reduced by managing systemic factors2 3. Key preventive measures include:

• Maintaining tight glycemic control to reduce retinal vascular damage2 3
• Controlling hypertension and hyperlipidemia to mitigate microvascular injury2 3
• Regular retinal screening for early detection and timely intervention2 3
• Lifestyle modifications such as healthy diet, physical activity, and smoking cessation3

Early diagnosis and treatment are critical to preserving vision and preventing progression to severe vision loss2 3.

Conditions Related to DME

DME often coexists with other diabetic eye complications due to shared microvascular damage from chronic hyperglycemia2 3. Related conditions include:

• Diabetic retinopathy: The underlying retinal vascular disease causing DME2 3
• Glaucoma: Optic nerve damage often linked to elevated intraocular pressure, with increased prevalence in diabetics2 3
• Cataracts: Lens opacities causing vision impairment, occurring earlier and more frequently in diabetic patients2 3
• Proliferative diabetic retinopathy: Characterized by neovascularization and fibrous tissue contraction, which can lead to tractional retinal detachment2 3

Macular edema further destabilizes retinal structure, increasing the risk of retinal detachment and vision loss3 .

Managing Life with DME

Living with DME requires ongoing medical care and lifestyle adjustments to maintain vision and quality of life2 3. Patients should:

• Adhere to regular eye examinations and treatment schedules2 3
• Manage systemic conditions such as diabetes, hypertension, and cholesterol3
• Use assistive devices and environmental modifications to support daily activities2
• Consult ophthalmologists promptly if vision changes occur3

Vision impairment severity varies; many patients maintain functional vision with appropriate therapy and support2 3.

Early detection and management of diabetic macular edema are essential to preserving vision and independence. Regular screening and timely treatment can prevent irreversible vision loss and improve quality of life. 23

Diabetic Macular Edema FAQs

Q: Can DME cause complete blindness?
A: Without treatment, DME can progress to severe vision loss, including legal blindness, but early and appropriate therapy can often preserve functional vision2 3.

Q: How often should diabetic patients have eye exams?
A: Patients with type 1 diabetes should begin screening five years after diagnosis, while those with type 2 diabetes should be screened at diagnosis and annually thereafter2 16.

Q: Are anti-VEGF injections painful?
A: Injections are performed under local anesthesia with numbing drops, and most patients experience minimal discomfort12 .

Q: Can lifestyle changes help with DME?
A: Yes, controlling blood sugar, blood pressure, and cholesterol, along with healthy diet and exercise, can reduce the risk and progression of DME2 3.